Table 4.
Multivariate analyses of risk factors for treatment to left lung or both lungs compared with the right lung and risk for developing cardiac conditions in patients diagnosed with non-small-cell lung cancer
| Adjusted model | Hazard ratio (95% confidence interval) | ||||
| Ischemic heart disease | Cardiomyopathy | Conduction disorders | Cardiac dysfunction | Heart failure | |
| Radiation therapy | |||||
| Radiation: R-side | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Radiation: L-side | 1.18 (1.05–1.34) | 0.99 (0.71–1.38) | 1.24 (0.84–1.84) | 1.10 (1.01–1.19) | 0.88 (0.79–0.98) |
| Radiation to both sides | 1.37 (0.94–1.99) | 0.70 (0.17–2.87) | 1.17 (0.27–5.00) | 0.85 (0.64–1.14) | 1.15 (0.81–1.63) |
| Chemoradiation | |||||
| Chemoradiation: R-side | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Chemoradiation: L-side | 1.29 (1.09–1.52) | 1.05 (0.68–1.62) | 0.96 (0.64–1.45) | 1.11 (1.00–1.24) | 1.31 (0.53–3.20) |
| Chemoradiation: both sides | 1.76 (1.11–2.78) | 1.09 (0.26–4.51) | 0.46 (0.06–3.36) | 1.06 (0.75–1.49) | 3.03 (0.31–30.1) |
All models adjusted for age, sex, ethnicity/race, socioeconomic status, comorbidity score, tumor size, positive number of nodes, tumor grade, histology, surgery, SEER areas, years of diagnosis, and pulmonary fibrosis using survival analysis, including interaction terms for ischemic heart disease for radiation therapy: radiation therapy and comorbidity score and for chemoradiation: chemoradiation and comorbidity score.
R, right; L, left; SEER, Surveillance, Epidemiology, and End Result. Statistically significant hazard ratios are in bold.